Back to top
more

AMN Healthcare Services (AMN)

(Delayed Data from NYSE)

$17.43 USD

17.43
643,813

-0.42 (-2.35%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $17.43 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 246)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

QIAGEN (QGEN) Gains From Innovation, Currency Headwind Ails

by Zacks Equity Research

The QuantiFERON franchise is a key driver behind QIAGEN's (QGEN) molecular diagnostics growth.

Zacks Equity Research

Brookdale Senior Living (BKD) Q4 Weighted Average Occupancy Up

by Zacks Equity Research

Brookdale Senior Living (BKD) witnesses 14 straight months of year-over-year increases in weighted average occupancy level.

Zacks Equity Research

Syneos Health (SYNH) to Launch Serplulimab With New Pact

by Zacks Equity Research

Syneos Health's (SYNH) new partnership will develop an advanced commercialization model to serve healthcare professionals and patients in the best possible way in today's changing environment.

Zacks Equity Research

Here's Why You Should Retain QIAGEN (QGEN) Stock for Now

by Zacks Equity Research

Investors are optimistic about QIAGEN (QGEN), led by progress in the test menu expansion strategy.

Zacks Equity Research

Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?

by Zacks Equity Research

Sector ETF report for PSCH

Zacks Equity Research

AMN Healthcare Services (AMN) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

AMN Healthcare Services (AMN) closed the most recent trading day at $110.88, moving -1.55% from the previous trading session.

Zacks Equity Research

Nevro's (NVRO) Preliminary Q4 Revenues Solid, Issues '23 Outlook

by Zacks Equity Research

Nevro's (NVRO) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its PDN business.

Zacks Equity Research

Here's Why Investors Should Buy Exact Sciences (EXAS) Stock

by Zacks Equity Research

Investors are optimistic about Exact Sciences (EXAS) on continued strength across the Screening and Precision Oncology businesses.

Zacks Equity Research

Are Investors Undervaluing AMN Healthcare Services (AMN) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Masimo (MASI) Gets Favorable Ruling in Apple Watch Patent Suit

by Zacks Equity Research

A U.S. Administrative Law Judge ruled that Apple watches infringe one of Masimo's (MASI) pulse oximeter patents. An import ban may follow for Apple watches.

Zacks Equity Research

Reasons to Retain West Pharmaceutical (WST) in Your Portfolio

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.

Zacks Equity Research

DexCom (DXCM) Announces Solid Preliminary Q4 Revenues

by Zacks Equity Research

DexCom's (DXCM) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its CGM sales.

Zacks Equity Research

QIAGEN (QGEN) Acquires the Forensics NGS Firm Verogen

by Zacks Equity Research

QIAGEN's (QGEN) acquisition of Verogen fortifies the company's position in the fast-growing field of Human ID and forensics.

Zacks Equity Research

Here's Why You Should Retain Veradigm (MDRX) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Veradigm (MDRX) owing to its strategic alliances.

Zacks Equity Research

Illumina (ILMN), Nashville Biosciences Partner With Amgen

by Zacks Equity Research

Illumina (ILMN) is currently keeping well with its goals to strengthen its foothold in the multi-billion gene sequencing market globally.

Zacks Equity Research

Teladoc (TDOC) Boosts Revenue Guidance, Shares Jump 4.1%

by Zacks Equity Research

Teladoc (TDOC) expects around $1 billion in revenues from its BetterHelp mental health business in 2022.

Zacks Equity Research

Myriad Genetics (MYGN) Ailed by Mounting Costs, FX Headwind

by Zacks Equity Research

Myriad Genetics' (MYGN) significant gross margin contraction and operating loss as a result of mounting cost pressure are concerning.

Zacks Equity Research

Abbott's (ABT) New Launch to Boost Blood Donation Experience

by Zacks Equity Research

Abbott's (ABT) mixed reality offers donors an innovative, immersive digital experience while giving blood.

Zacks Equity Research

Here's Why Investors Should Retain SmileDirectClub (SDC) Now

by Zacks Equity Research

Investors are optimistic about SmileDirectClub (SDC) on continued strategic partnerships and expansion in the teledentistry space.

Zacks Equity Research

Here's Why You Should Retain QuidelOrtho (QDEL) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its strong product portfolio.

Zacks Equity Research

LabCorp (LH) Oncology Arm Gains Traction, Margin Pressure Stays

by Zacks Equity Research

In terms of portfolio enhancement, LabCorp (LH) enters into a collaboration with Becton, Dickinson and Company to advance in life-changing treatments for cancer and other diseases.

Zacks Equity Research

QuidelOrtho (QDEL) Reports Solid Preliminary Q4 Revenues

by Zacks Equity Research

QuidelOrtho's (QDEL) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its non-COVID-19 product sales.

Zacks Equity Research

Baxter (BAX) Plans to Form Standalone Kidney Care Company

by Zacks Equity Research

Baxter (BAX) plans several strategic actions, including spin-off of Renal Care and Acute Therapies global business units into an independent, publicly traded company to simplify its operating model.

Zacks Equity Research

Here's Why You Should Hold on to Teleflex (TFX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Teleflex (TFX) on strong preference for the UroLift system.

Zacks Equity Research

Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio

by Zacks Equity Research

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.